 Shares of Cassava Sciences NASDAQ: SAVA stock are in focus after the company announced that it would begin an open-label study on its investigational Alzheimers disease AD drug, simufilam. The trial will be eligible for patients who complete either one of its ongoing Phase 3 studies. 